University of Göttingen

iXCells Biotechnologies Strengthens Leadership Team; Welcomes New CEO

Retrieved on: 
Thursday, January 18, 2024
Research, Infectious Diseases, Genetics, Stem Cells, Biotechnology, Health, Pharmaceutical, Other Science, Science, Columbia Business School, Patient, University, Molecular diagnostics, IPSC, Biophysical chemistry, Sigma-Aldrich, SGS, Thermo Fisher Scientific, B cell, Business development, Executive, Disease, Drug development, QIAGEN, University of Göttingen, Doctor of Philosophy, Genome, Synthetic biology, Alumni, RUO, Nobel Prize, Growth, Management

To help drive our next phase of growth, we’re thrilled to warmly welcome Helge Bastian to our executive team.

Key Points: 
  • To help drive our next phase of growth, we’re thrilled to warmly welcome Helge Bastian to our executive team.
  • Helge brings to iXCells a wealth of entrepreneurial and intrapreneurial leadership experience across the life sciences and healthcare space in building businesses for small and large companies with a proven track record of value creation.
  • In addition, Dr. Bastian led oncology focused Indivumed and M2GEN (now Aster Insights) as Managing Director & Chief Commercial Officer and CEO, respectively.
  • Dr. Lynn Zhang will continue to serve on iXCells’ board of directors and assist with transitioning CEO leadership responsibilities in the coming months.

eGenesis Announces Knut Niss as Chief Technology Officer

Retrieved on: 
Tuesday, January 24, 2023
Cell, Mustang, Molecular biology, Regenerative medicine, Biotechnology, CMC, Hospital, Biogen, Organ transplantation, Manifest and latent functions and dysfunctions, Humboldt University of Berlin, Patient, Cell therapy, Dana–Farber Cancer Institute, University of Göttingen, Doctor of Philosophy, Merck Millipore, Pharmaceutical industry, Operation, Biology, Pfizer

CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.
  • “We are pleased to welcome Knut to the team and are confident he will help us advance our goal of transforming the treatment paradigm for organ failure,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis.
  • “Synthetic biology and gene engineering are core components of our approach to developing high-quality, transplantable organs that ultimately save lives.
  • “Powered by a strong technological platform, eGenesis is well-positioned to address the hurdles that have hindered the field of xenotransplantation to date,” Dr. Niss said.

ONWARD Announces New Board Appointment

Retrieved on: 
Monday, June 13, 2022
Professional Services, Health, Medical Devices, Finance, Research, Science, Biotechnology, Science, ARC, Euronext, Company, Board of directors, High Tech Campus Eindhoven, GlaxoSmithKline, Johns Hopkins University, CEO, Nature, London School of Economics, Philosophy, politics and economics, University of Göttingen, London, Business administration, Multimedia, Hyperreflexia, International economics, University of Oxford, FDA, Growth, Master of Science, Spinal cord injury, Technology, Health, Movement, Quality of life, Judgement, Industry, Behavioral health outcomes management, National College of Business Administration and Economics, Pharmaceutical industry, Risk management, Politics, Economics, Philosophy, Health policy

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the appointment of Kristina Dziekan to its Board of Directors.

Key Points: 
  • ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the appointment of Kristina Dziekan to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20220613005579/en/
    Kristina strengthens our Board, bringing judgment and expertise needed for our next phase of growth, said Dave Marver, CEO of ONWARD.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX.